Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS).

Annals of hematology·2025
Same author

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.

Leukemia·2024
Same author

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study.

Epidemiology and psychiatric sciences·2022
Same author

Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter.

Blood·2021
Same author

Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.

Annals of hematology·2020
Same author

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Leukemia·2020

Related Experiment Video

Updated: May 14, 2026

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis
16:01

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis

Published on: January 26, 2015

Mast cell activation syndromes: definition and classification.

P Valent1

  • 1Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria. peter.valent@meduniwien.ac.at

Allergy
|February 16, 2013
PubMed
Summary

Mast cell activation (MCA) can range from mild to life-threatening, influenced by genetics and allergens. Diagnosing mast cell activation syndrome (MCAS) requires identifying recurrent symptoms and elevated mediators, aiding patient management.

More Related Videos

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

Related Experiment Videos

Last Updated: May 14, 2026

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis
16:01

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis

Published on: January 26, 2015

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

Area of Science:

  • Immunology
  • Allergy and Clinical Immunology

Background:

  • Mast cell activation (MCA) is implicated in diverse conditions like allergies, inflammatory reactions, and mastocytosis.
  • MCA symptoms vary in severity, influenced by genetic factors, mast cell characteristics, allergen type, IgE presence, and comorbidities.
  • Severe MCA can be indicated by a significant rise in serum tryptase levels above baseline.

Purpose of the Study:

  • To elucidate the complexity of mast cell activation syndrome (MCAS) and its classification.
  • To highlight the importance of detailed knowledge for effective patient management and therapy.

Main Methods:

  • Clinical observation and diagnosis of mast cell activation syndrome (MCAS).
  • Classification of MCAS based on underlying conditions: primary (KIT-mutated mast cells), secondary (underlying inflammation, e.g., IgE allergy), and idiopathic (no identifiable cause).
  • Assessment of mast cell-derived mediators in biological fluids and response to treatment.

Main Results:

  • Recurrent symptoms with elevated mast cell mediators and treatment responsiveness support an MCAS diagnosis.
  • MCAS classification identifies distinct patient subgroups based on the presence of KIT mutations or underlying inflammatory conditions.
  • Multiple contributing factors can synergize in MCAS, leading to severe or life-threatening anaphylaxis.

Conclusions:

  • Understanding the pathogenesis and complexity of MCAS is crucial for accurate diagnosis.
  • Accurate diagnosis of MCAS, considering its subtypes and contributing factors, significantly improves patient management and therapeutic strategies.
  • Detailed knowledge of MCAS aids in differentiating it from other conditions and tailoring treatments effectively.